Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...

Pfizer (NYSE:PFE | PFE Price Prediction) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is ...

It looks like Pfizer Inc. ( NYSE:PFE ) is about to go ex-dividend in the next three days. The ex-dividend date is ...

Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.

Pfizer will report its first-quarter 2026 earnings after the market closes, with analysts expecting EPS of $0.72, down 21.7% year over year, and revenue of $13.8 billion. The company’s high-yield ...

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...

Hey, can Pfizer break out of its multi-year rut? Now, a lot depends on the presentation because I haven’t seen any needle ...

The pharmaceutical giant just extended the lifespan of one of its top drugs.

Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...

Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne ...

The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question ...

Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...